Ultimine (Ferrous Ferric Iron)

Ultimine is a proprietary iron supplement containing both ferrous (Fe2+) and ferric (Fe3+) iron forms designed for enhanced absorption. The dual-valence formulation aims to optimize iron bioavailability through multiple intestinal transport pathways.

Origin & History

Ultimine (Ferrous Ferric Iron) appears to describe a mixed ferrous (Fe²⁺) and ferric (Fe³⁺) iron compound, though it is not identified as a recognized branded ingredient in available biomedical sources. Iron compounds are typically synthesized chemically via reactions like sulfuric acid with iron or oxidizing agents, belonging to the inorganic chemical class of transition metal salts.

Historical & Cultural Context

No historical or traditional medicine uses are documented for Ultimine in systems like Ayurveda or TCM. Iron salts have primarily industrial applications rather than traditional biomedical uses.

Health Benefits

• No clinical evidence available - No studies document health benefits specifically for Ultimine
• Iron deficiency treatment potential - General ferrous iron supplements are established for treating iron deficiency, though no data exists for this specific formulation
• No verified cardiovascular benefits - No clinical trials support cardiovascular claims for Ultimine
• No documented energy support - No research validates energy-related benefits for this compound
• No proven immune function support - No studies demonstrate immune system benefits for Ultimine

How It Works

Ultimine provides ferrous iron (Fe2+) that is directly absorbed via divalent metal transporter 1 (DMT1) in duodenal enterocytes, while ferric iron (Fe3+) requires reduction by duodenal cytochrome B reductase before absorption. The dual-form approach theoretically maximizes iron uptake by utilizing both heme and non-heme iron transport mechanisms. Once absorbed, iron is incorporated into transferrin for systemic distribution to tissues requiring iron for hemoglobin synthesis and cellular respiration.

Scientific Research

No clinical trials, RCTs, meta-analyses, or PubMed PMIDs are available for Ultimine as a branded ingredient. The research dossier indicates that while ferrous sulfate is a standard iron supplement with established efficacy, no mixed ferrous-ferric branded studies exist for this specific product.

Clinical Summary

No clinical trials have specifically evaluated Ultimine's efficacy or safety profile. While general ferrous sulfate and ferric compounds have extensive research supporting their use in iron deficiency anemia treatment, the specific ferrous-ferric combination in Ultimine lacks peer-reviewed clinical validation. Standard iron supplements typically show 10-30% absorption rates and effectively raise hemoglobin levels by 1-2 g/dL over 4-8 weeks in iron-deficient patients. The theoretical advantages of Ultimine's dual-iron formulation remain unproven without dedicated clinical studies.

Nutritional Profile

Ultimine is a proprietary iron compound containing both ferrous (Fe²⁺) and ferric (Fe³⁺) iron in a combined oxidation state formulation. As a mineral ingredient, it contains no macronutrients (zero protein, fat, or carbohydrates), no dietary fiber, and no vitamins inherently. The active constituent is elemental iron delivered in a mixed-valence form. Typical supplemental iron doses in comparable ferrous/ferric compounds range from 15–65 mg elemental iron per serving, though Ultimine-specific dosing data is not publicly documented. The dual iron state (ferrous + ferric) is theoretically relevant to bioavailability: ferrous iron (Fe²⁺) is the primary absorbable form in the duodenum via divalent metal transporter-1 (DMT-1), while ferric iron (Fe³⁺) requires reduction by duodenal cytochrome B (Dcytb) prior to absorption. The mixed-valence formulation may be designed to optimize this reduction step, potentially improving absorption compared to strictly ferric compounds. No published bioavailability studies specific to Ultimine exist; however, ferrous iron salts generally achieve 10–35% absorption in iron-deficient individuals and 1–10% in iron-replete individuals. No additional micronutrients, phytonutrients, or bioactive compounds are documented for this ingredient beyond the iron content itself.

Preparation & Dosage

No clinically studied dosages, forms, or standardization are documented for Ultimine. General ferrous sulfate dosing ranges from 200-325 mg elemental iron daily, but this lacks relevance without product-specific data. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients identified due to lack of research

Safety & Interactions

Iron supplements commonly cause gastrointestinal side effects including nausea, constipation, and stomach upset, with similar effects expected from Ultimine. Iron absorption decreases significantly when taken with calcium, tea, coffee, or dairy products, while vitamin C enhances absorption. Iron supplements can reduce absorption of tetracycline antibiotics, levothyroxine, and bisphosphonates when taken concurrently. Pregnant women should consult healthcare providers before using iron supplements, as excessive iron intake may cause complications.